Idera Pharmaceuticals Inc (NASDAQ:IDRA) announce plans to initiate clinical development of its lead compound, IMO-8400, for the treatment of patients with polymyositis and patients with dermatomyositis, two orphan autoimmune diseases with high unmet clinical needs. Idera Pharmaceuticals Inc (NASDAQ:IDRA) stock performance was 1.23% in last session and finished the day at $ 2.47. Traded volume was 2,242,021 shares in the last session and the average … Continue reading NASDAQ Active Stocks: Idera Pharmaceuticals Inc (NASDAQ:IDRA), Synergy Pharmaceuticals Inc (NASDAQ:SGYP), Amarin Corporation plc (ADR) (NASDAQ:AMRN), Depomed Inc (NASDAQ:DEPO)